Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating adding BAY 1895344 with radiation therapy to pembrolizumab for recurrent head and neck squamous cell carcinomas, aiming to assess safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma of the Head and Neck
• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Paranasal Sinus Cancer
• Salivary Gland Cancer

Drugs mentioned

• BAY 1895344 (BAY 1895344)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING